Slide 1: Fiscal First Quarter 2026 Financial Results
Fiscal First Quarter 2026 Financial Results EARNINGS PRESENTATION February 4, 2026 © 2026 Azenta, Inc. • All rights reserved
Slide 2: Safe Harbor Statement
Safe Harbor Statement Safe Harbor Statement This presentation contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding future financial performance including our
Slide 3: Azenta Life Sciences Q1 2026 Financial Overview
Azenta Life Sciences Q1 2026 Financial Overview QUARTER ENDED DECEMBER 31, 2025 Performance Highlights Adjusted Revenue Q1’26 Revenue EBITDA margin • Revenue $149M, up 1% reported and down 1% organic • Flat % organic growth in Multiomics and down 2% organic $149M 8.5% in SMS • Main areas of growth i
Slide 4: Q1 2026 Selected Non-GAAP Financial Measures
Q1 2026 Selected Non-GAAP Financial Measures QUARTER ENDED DECEMBER 31, 2025 Total Azenta Organic Growth $ millions except EPS and percentages Non-GAAP $ millions Q1'25 Q1'26 YtY Revenue $ 147 $ 149 1% Gross profit 70 66 (7%) Q1’25 Q1’26 YtY % 47.7% 44.1% (3.6) pts. Reported 147 149 1% R&D 7 9 29% F
Slide 5: Q1 2026 Performance by Segment
Q1 2026 Performance by Segment ORGANIC UNLESS OTHERWISE NOTED Revenue by Segment Sample Management Solutions (“SMS”) 45% • HSD growth in Sample Storage Multiomics • LSD growth in Consumables and (GENEWIZ) • $67 million Instruments • 1% YoY reported • Flat YoY organic • $149 million Multiomics • 1% r
Slide 6: Summary Consolidated Balance Sheet
Summary Consolidated Balance Sheet QUARTER ENDED DECEMBER 31, 2025 Balance Sheet $ millions Sep Dec 2025 2025 QtQ Cash, restricted cash, short term marketable securities 343 412 69 Accounts receivable, net 142 142 0 • $581M of cash, cash equivalents, restricted Inventories 75 82 8 cash and marketabl
Slide 7: Summary Consolidated Cash Flow
Summary Consolidated Cash Flow QUARTER ENDED DECEMBER 31, 2025 Cash Flow $ millions Q1'26 • $581M of cash, cash equivalents, restricted Cash, restricted cash and marketable securities - Beginning 559 cash and marketable securities, including Net income (15) $10M of cash in current assets held for sa
Slide 8: Fiscal Year 2026 Guidance
Fiscal Year 2026 Guidance FY’2026 Organic Growth: 3% to 5% YoY Revenue Sample Management Solutions: MSD Multiomics: LSD Adjusted EBITDA Approximately 300bps of Adjusted EBITDA margin expansion Interest Income: $16M - $18M Other Tax Rate: 27% - 29% Note: As of 11/21/2025 Per Q4’25 Guidance © 2025 202
Slide 9: Appendix
Appendix © 2026 Azenta, Inc. • All rights reserved
Slide 10: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation TOTAL AZENTA $ millions except percentages $ millions, except EPS Q1 F Y 25 Q2 F Y 25 Q3 F Y 25 Q4 F Y 25 F Y 25 Q1 F Y 26 Revenue 147.4 143.3 143.9 159.2 593.8 148.6 G AAP gross prof it 68.8 62.8 66.4 72.3 270.3 63.7 Gross profit margin 46.7% 43.8% 46.2% 45.4% 45.5%
Slide 11: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation CONTINUING OPERATIONS - SEGMENTS $ millions except percentages Q1 F Y 25 Q2 F Y 25 Q3 F Y 25 Q4 F Y 25 F Y 25 Q1 F Y 26 Mult iomics Revenue 66.3 63.5 66.2 73.2 269.2 67.2 G ross prof it 29.7 26.6 26.2 31.1 113.6 27.9 Gross profit margin 44.8% 41.9% 39.6% 42.5% 42.2% 4
Slide 12: Net Income to Adjusted EBITDA Reconciliation
Net Income to Adjusted EBITDA Reconciliation CONTINUING OPERATIONS $ millions except percentages Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 FY25 Q1 FY26 Net income (11.0) (47.7) (48.0) 50.9 (55.8) (15.4) (Income) Loss from discontinued operations, net of tax 3.9 27.9 47.7 0.8 80.2 10.2 Net income (Loss) f rom
Slide 13: Calculation of Non-GAAP Organic Revenue
Calculation of Non-GAAP Organic Revenue CONTINUING OPERATIONS Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 FY25 Q1 FY26 Revenue 4% 5% (0%) 6% 4% 1% Acquisitions/divestitures 0% 0% 0% 0% 0% 0% Currency exchange rates (0%) 1% (2%) (2%) (1%) (2%) Organic revenue 3% 6% (2%) 4% 3% (1%) Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25